Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Octenidine and Sodium Hypochlorite for Pulp Irrigation in Direct Pulp Capping

NCT06946719 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2024-06-01
Last updated
2025-04-27

Condition(s) studied

Pulp Exposure, Dental

Investigational drug(s) / intervention(s)

pulp lavage Octenidinepulp lavage NaOCl

pulp lavage Octenidine: Use of Octenidine as a pulp irrigation solution in pulp capping for mature permanent teeth

pulp lavage NaOCl: Use of NaOCl as a pulp irrigation solution in pulp capping for mature permanent teeth

Study summary

In the included patients, after complete removal of caries from the entire cavity, the exposed pulp will be treated with either a 2.5% NaOCl or 0.1% Octenidine solution. Subsequently, the cavity will be restored using calcium silicate cement, glass ionomer cement, and composite resin. Postoperatively, the patient's pain level will be assessed using the Visual Analogue Scale (VAS) at 24 and 72 hours, as well as on the 7th day. Responses to pulp sensitivity tests and periapical radiographs will be evaluated at 6 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Asymptomatic posterior tooth (premolar or molar) with deep caries * A healthy periodontal status, normal probing depth, and restorable. * Negative responses to percussion and palpation tests while responding positively to cold testing and electric pulp testing Exclusion Criteria: * Participants will be excluded if they had any systemic diseases * A negative response to cold testing and electric pulp testing. * Presence of a sinus tract, absence of pulp exposure following complete caries removal, or necrotic or partially necrotic pulp tissue

Primary outcome measure(s)

  • Post operative pain — 24 hours
    Use of the Visual Analog Scale (VAS) following the procedure
  • Post operative pain — 48 hours
    Use of the Visual Analog Scale (VAS) following the procedure
  • Post operative pain — 72 hours
    Use of the Visual Analog Scale (VAS) following the procedure

Trial sites (1)

FacilityCityRegionStatus
Cemre Koç Aydin Efeler
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06946719 on ClinicalTrials.gov ↗ ← All trials in Turkey